Insmed Incorporated develops and commercializes biopharmaceutical therapies for serious diseases, with a commercial respiratory portfolio that includes ARIKAYCE® (amikacin liposome inhalation suspension) and BRINSUPRI® (brensocatib). Its pipeline spans pulmonary, inflammatory, immunology and rare-disease programs, including TPIP and INS1148, alongside early research in gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining and synthetic rescue.
Recurring company news covers product revenue trends, regulatory authorizations and label-development activity for ARIKAYCE and BRINSUPRI, clinical data in MAC lung disease, non-cystic fibrosis bronchiectasis and inflammatory conditions, and presentations at medical and investor conferences. Updates also include portfolio-prioritization decisions, financial results, employee equity inducement grants and other governance-related announcements.
Insmed Incorporated (Nasdaq: INSM) presented new findings at the ATS 2022 International Conference, showcasing significant benefits of ARIKAYCE and brensocatib. A retrospective study revealed a reduction in all-cause hospitalizations from 35.9% to 23.0% in patients following ARIKAYCE treatment, with similar improvements in respiratory-related hospitalizations. Additionally, post-hoc analyses of the WILLOW study indicated a favorable benefit-risk profile for brensocatib, noting a low number needed to treat (NNT) of 6-7 and a negative number needed to harm (NNH), suggesting a lower risk of severe adverse events compared to placebo.
Insmed Incorporated (Nasdaq: INSM), a biopharmaceutical company focused on rare diseases, will present in a fireside chat at the H.C. Wainwright Annual Global Life Sciences Conference. The event is scheduled for on-demand viewing on May 24, 2022, at 7:00 a.m. ET, accessible through the company's investor relations site. Insmed is known for its first-in-disease therapy for chronic lung disease and has a pipeline aimed at unmet medical needs in inflammatory and pulmonary disorders. The webcast will be available for 30 days post-presentation.
On May 6, 2022, Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 10 new employees as per NASDAQ Listing Rule 5635(c)(4). These awards include options to purchase 70,080 shares of common stock at $22.45 per share, the closing price on May 2, 2022. The options have a 10-year term with a four-year vesting schedule. Insmed is focused on transforming the lives of patients with serious and rare diseases, with its first commercial product approved in the U.S., Europe, and Japan.
Insmed Incorporated (Nasdaq:INSM) reported strong Q1 2022 results, achieving 32% year-over-year growth with total revenue of $53.1 million, driven by ARIKAYCE sales of $40.8 million in the U.S. The company maintains its 2022 revenue guidance of at least 30% growth and a cash runway into 2024. Seven clinical trials are ongoing, including the Phase 3 ASPEN study for brensocatib. Despite a net loss of $94.6 million for the quarter, Insmed's financial position remains strong as it continues to invest in expansion and research initiatives.
Insmed, a biopharmaceutical company focused on rare diseases, plans to release its Q1 2022 financial results on May 5, 2022. The management will conduct a conference call at 8:30 a.m. ET on the same day to discuss the results and provide a business update. Interested parties can join the call via phone or through a live webcast on the company's website. Insmed aims to transform lives with innovative therapies and is progressing in various serious unmet medical needs.
Insmed Incorporated (Nasdaq: INSM) announced on April 7, 2022, the granting of inducement awards to 20 new employees as part of NASDAQ Listing Rule 5635(c)(4). Each employee received options to purchase a total of 107,680 shares at an exercise price of $24.47 per share, which was the closing price on April 1, 2022. The options come with a 10-year term and a four-year vesting schedule. Insmed focuses on developing therapies for serious and rare diseases, with its first product approved in the US, Europe, and Japan.
Insmed (Nasdaq: INSM) will present seven posters at the ATS 2022 International Conference, highlighting data on ARIKAYCE, brensocatib, and treprostinil palmitil inhalation powder. Key presentations include real-world evidence on ARIKAYCE's effectiveness in reducing hospitalizations and an analysis of the benefit-risk profile of brensocatib in bronchiectasis patients. The conference, set for May 13-18, 2022, in San Francisco, is a platform for the latest advancements in treatments for serious diseases.
Insmed Incorporated (Nasdaq: INSM) announced the granting of inducement awards to 15 new employees as a material inducement for their employment, as per NASDAQ Listing Rule 5635(c)(4). On March 1, 2022, the employees were granted options to purchase a total of 61,090 shares at an exercise price of $23.99 per share, reflecting the closing price on that date. The options have a 10-year term and a four-year vesting schedule, with 25% vesting on the first anniversary and subsequent vesting every six months.
Insmed Incorporated (Nasdaq: INSM) will present at the Cowen 42nd Annual Health Care Conference on March 9, 2022, at 9:10 a.m. ET. The live fireside chat will be accessible via the company's investor relations section on their website, with an archive available for 30 days post-event. Insmed focuses on treating serious and rare diseases and has launched a first-in-disease therapy approved in the U.S., Europe, and Japan. The company is also developing therapies for unmet needs in inflammatory diseases and rare pulmonary disorders.
Insmed Incorporated (Nasdaq: INSM) reported a strong fourth quarter and full-year 2021, with total revenue reaching $56.1 million for Q4 and $188.5 million for the full year, a rise from $164.4 million in 2020. The company saw ARIKAYCE net sales of $159.5 million in the U.S. and launched the product in several European markets. However, Insmed also reported a net loss of $113 million in Q4 2021, leading to a full-year loss of $434.7 million. Despite these losses, the company expects ARIKAYCE revenues to grow by at least 30% in 2022, supported by a cash position of $766.8 million.